Lassa fever pathophysiology: Difference between revisions
YazanDaaboul (talk | contribs) |
m (Changes made per Mahshid's request) |
||
(12 intermediate revisions by 3 users not shown) | |||
Line 2: | Line 2: | ||
{{Lassa fever}} | {{Lassa fever}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Lassa fever may be transmitted from either infected animals (typically rodents) or humans following exposure to body fluids and excretions/secretions from the respiratory tract or GI tract. Following transmission, Lassa virus infects the endothelium and replicates intracellularly using an L-polymerase enzyme and nucleocapsid protein NP, which synthesize ribonucleoprotein (RNP) that produces mRNA and antigenomic RNA required for transcription. NP protein helps the virus evade the host immune system. Following transcription, vascular dysfunction ensues, resulting in the development of clinical manifestations of the disease. Although all organs may potentially be infected, the liver is a common target organ, and hepatitis/hepatic necrosis is typical following Lassa fever infection. | Lassa fever may be transmitted from either infected animals (typically rodents) or humans following exposure to body fluids and excretions/secretions from the respiratory tract or GI tract. Following transmission, Lassa virus infects the endothelium and replicates intracellularly using an L-polymerase enzyme and nucleocapsid protein NP, which synthesize ribonucleoprotein (RNP) that produces mRNA and antigenomic RNA required for transcription. NP protein helps the virus evade the host immune system. Following transcription, vascular dysfunction ensues, resulting in the development of clinical manifestations of the disease. Although all organs may potentially be infected, the liver is a common target organ, and hepatitis/hepatic necrosis is typical following Lassa fever infection. | ||
Line 18: | Line 16: | ||
==Cellular Pathogenesis== | ==Cellular Pathogenesis== | ||
===Host Cell Entry=== | |||
* Following transmission, Lassa virus primarily infects the [[endothelial cells]]. | * Following transmission, Lassa virus primarily infects the [[endothelial cells]]. | ||
* The [[Lassa virus]] gains entry into the host cell by means of the [[cell-surface receptor]] the alpha-[[dystroglycan]] (alpha-DG),<ref name="pmid10888638">{{cite journal| author=Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH et al.| title=Genetic diversity among Lassa virus strains. | journal=J Virol | year= 2000 | volume= 74 | issue= 15 | pages= 6992-7004 | pmid=10888638 | doi= | pmc=PMC112216 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10888638 }} </ref> a versatile [[receptor]] for [[protein]]s of the [[extracellular matrix]]. | |||
* Unlike most enveloped viruses which use [[clathrin]]-coated pits for cellular entry and bind to their [[receptors]] in a pH dependent fashion, Lassa virus instead undergoes cellular entry via endocytosis using alpha-dystroglycan receptor (ubiquitously expressed cell surface receptor), independent of either [[clathrin]], [[caveolin]], [[dynamin]] or [[actin]]. | |||
*Once within the [[cell]], the [[viruses]] are rapidly delivered to [[endosomes]] via vesicular trafficking. Once in contact with the [[endosome]], Lassa virus evades endosomal degradation using envelope glycoproteins, which mediate a pH-dependent binding and [[membrane fusion]]. | |||
===RNA Synthesis=== | |||
*Intracellular RNA synthesis is initiated within an L-polymerase enzyme, which utilizes viral RNA templates and nucleocapsid protein NP to synthesize viral ribonucleoprotein (RNP). Once synthesized, RNP is transmitted to the host cell cytoplasm, and transcription of mRNA and antigenomic RNA (agRNA).<ref name="pmid23202452">{{cite journal| author=Yun NE, Walker DH| title=Pathogenesis of Lassa fever. | journal=Viruses | year= 2012 | volume= 4 | issue= 10 | pages= 2031-48 | pmid=23202452 | doi=10.3390/v4102031 | pmc=PMC3497040 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23202452 }}</ref> | *Intracellular RNA synthesis is initiated within an L-polymerase enzyme, which utilizes viral RNA templates and nucleocapsid protein NP to synthesize viral ribonucleoprotein (RNP). Once synthesized, RNP is transmitted to the host cell cytoplasm, and transcription of mRNA and antigenomic RNA (agRNA).<ref name="pmid23202452">{{cite journal| author=Yun NE, Walker DH| title=Pathogenesis of Lassa fever. | journal=Viruses | year= 2012 | volume= 4 | issue= 10 | pages= 2031-48 | pmid=23202452 | doi=10.3390/v4102031 | pmc=PMC3497040 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23202452 }}</ref> | ||
===Host Immune Response=== | |||
*Lassa fever evades the host immune system by production of NP protein, which has an exonuclease activity and causes the inhibition of host type I IFN signaling.<ref name="pmid16940530">{{cite journal| author=Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC| title=Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. | journal=J Virol | year= 2006 | volume= 80 | issue= 18 | pages= 9192-9 | pmid=16940530 | doi=10.1128/JVI.00555-06 | pmc=PMC1563941 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16940530 }} </ref> | *Lassa fever evades the host immune system by production of NP protein, which has an exonuclease activity and causes the inhibition of host type I IFN signaling.<ref name="pmid16940530">{{cite journal| author=Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC| title=Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. | journal=J Virol | year= 2006 | volume= 80 | issue= 18 | pages= 9192-9 | pmid=16940530 | doi=10.1128/JVI.00555-06 | pmc=PMC1563941 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16940530 }} </ref> | ||
*Endothelial dysfunction results in the release of pro-inflammatory cytokines and cell mediators<ref name="pmid23202452">{{cite journal| author=Yun NE, Walker DH| title=Pathogenesis of Lassa fever. | journal=Viruses | year= 2012 | volume= 4 | issue= 10 | pages= 2031-48 | pmid=23202452 | doi=10.3390/v4102031 | pmc=PMC3497040 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23202452 }} </ref>, which in turn cause [[platelet]] dysfunction, hepatic necrosis, suppression of cardiac function, and development of Lassa fever-associated clinical manifestations, including facial edema, pleural and pericardial effusions, and hypovolemic shock. | *Endothelial dysfunction results in the release of pro-inflammatory cytokines and cell mediators<ref name="pmid23202452">{{cite journal| author=Yun NE, Walker DH| title=Pathogenesis of Lassa fever. | journal=Viruses | year= 2012 | volume= 4 | issue= 10 | pages= 2031-48 | pmid=23202452 | doi=10.3390/v4102031 | pmc=PMC3497040 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23202452 }} </ref>, which in turn cause [[platelet]] dysfunction, hepatic necrosis, suppression of cardiac function, and development of Lassa fever-associated clinical manifestations, including facial edema, pleural and pericardial effusions, and hypovolemic shock. | ||
*Lassa fever may potentially infect all organs, but the liver and auditory sensorineural system are commonly involved. | |||
*Failure of the host to mount an adequate cellular [[immune response]] to control viral dissemination, along with disseminated replication in [[tissues]] and absence of neutralizing [[antibodies]], results in host death.<ref name="pmid20360949">{{cite journal| author=Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M et al.| title=T cell-dependence of Lassa fever pathogenesis. | journal=PLoS Pathog | year= 2010 | volume= 6 | issue= 3 | pages= e1000836 | pmid=20360949 | doi=10.1371/journal.ppat.1000836 | pmc=PMC2847900 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20360949 }} </ref> Prompt host immune response is critical for host survival, and fatal Lassa fever is often characterized by impaired or delayed [[cellular immunity]]<ref name="CDC">{{cite web | title = The Centers for Disease Control and Prevention | url =http://www.cdc.gov/vhf/lassa/transmission/index.html }}</ref>. | |||
==Genetics== | |||
* | *Replication for [[Lassa virus]] is very rapid and demonstrates a temporal control.<ref name="pmid16629503">{{cite journal| author=Lashley FR| title=Emerging infectious diseases at the beginning of the 21st century. | journal=Online J Issues Nurs | year= 2006 | volume= 11 | issue= 1 | pages= 2 | pmid=16629503 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16629503 }} </ref> | ||
*The initial replication step is transcription of [[mRNA]] copies of the negative (minus-sense) genome. This process ensures an adequate supply of viral proteins for subsequent steps of replication, as the NP and L proteins are translated from the [[mRNA]]. | |||
*Following the initial replication step, the positive (plus-sense) [[genome]] then synthesizes viral complementary [[RNA]] (vcRNA) copies of itself. The vcRNA copies are then used to synthesize more mRNA and to serve as templates for the production of more negative-sense progeny. The [[mRNA]] synthesized from [[vcRNA]] are then translated to produce GP and Z proteins. | |||
*This temporal control allows the spike proteins to be produced last, and therefore, delay recognition by the host [[immune system]]. | |||
==Gross Pathology== | ==Gross Pathology== | ||
Line 38: | Line 46: | ||
*Gastrointestinal mucosal [[petechiae]] | *Gastrointestinal mucosal [[petechiae]] | ||
*[[Renal tubular injury]] | *[[Renal tubular injury]] | ||
*[[Interstitial nephritis]] | *[[Interstitial nephritis]] | ||
==Microscopic Pathology== | ==Microscopic Pathology== | ||
Line 69: | Line 77: | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Biological weapons]] | [[Category:Biological weapons]] | ||
Latest revision as of 18:09, 18 September 2017
Lassa fever Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lassa fever pathophysiology On the Web |
American Roentgen Ray Society Images of Lassa fever pathophysiology |
Risk calculators and risk factors for Lassa fever pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Lassa fever may be transmitted from either infected animals (typically rodents) or humans following exposure to body fluids and excretions/secretions from the respiratory tract or GI tract. Following transmission, Lassa virus infects the endothelium and replicates intracellularly using an L-polymerase enzyme and nucleocapsid protein NP, which synthesize ribonucleoprotein (RNP) that produces mRNA and antigenomic RNA required for transcription. NP protein helps the virus evade the host immune system. Following transcription, vascular dysfunction ensues, resulting in the development of clinical manifestations of the disease. Although all organs may potentially be infected, the liver is a common target organ, and hepatitis/hepatic necrosis is typical following Lassa fever infection.
Transmission
Animal to Human
- Infection in humans typically occurs via exposure to animal (typically rodent) excrement through the respiratory or gastrointestinal tracts.
- Inhalation of tiny particles of infected aerosol is thought to be the most significant means of exposure, but transmission through direct exposure of infection to skin wounds or mucous membranes.
- Handling of dead infected animals has also been associated with the transmission of Lassa virus.
Human to Human
- Lassa virus may be transmitted following exposure to blood, tissue, secretions (including breast milk), or excretions of an infected individual.
- The virus cannot be transmitted without the exchange of body fluids.
Cellular Pathogenesis
Host Cell Entry
- Following transmission, Lassa virus primarily infects the endothelial cells.
- The Lassa virus gains entry into the host cell by means of the cell-surface receptor the alpha-dystroglycan (alpha-DG),[1] a versatile receptor for proteins of the extracellular matrix.
- Unlike most enveloped viruses which use clathrin-coated pits for cellular entry and bind to their receptors in a pH dependent fashion, Lassa virus instead undergoes cellular entry via endocytosis using alpha-dystroglycan receptor (ubiquitously expressed cell surface receptor), independent of either clathrin, caveolin, dynamin or actin.
- Once within the cell, the viruses are rapidly delivered to endosomes via vesicular trafficking. Once in contact with the endosome, Lassa virus evades endosomal degradation using envelope glycoproteins, which mediate a pH-dependent binding and membrane fusion.
RNA Synthesis
- Intracellular RNA synthesis is initiated within an L-polymerase enzyme, which utilizes viral RNA templates and nucleocapsid protein NP to synthesize viral ribonucleoprotein (RNP). Once synthesized, RNP is transmitted to the host cell cytoplasm, and transcription of mRNA and antigenomic RNA (agRNA).[2]
Host Immune Response
- Lassa fever evades the host immune system by production of NP protein, which has an exonuclease activity and causes the inhibition of host type I IFN signaling.[3]
- Endothelial dysfunction results in the release of pro-inflammatory cytokines and cell mediators[2], which in turn cause platelet dysfunction, hepatic necrosis, suppression of cardiac function, and development of Lassa fever-associated clinical manifestations, including facial edema, pleural and pericardial effusions, and hypovolemic shock.
- Lassa fever may potentially infect all organs, but the liver and auditory sensorineural system are commonly involved.
- Failure of the host to mount an adequate cellular immune response to control viral dissemination, along with disseminated replication in tissues and absence of neutralizing antibodies, results in host death.[4] Prompt host immune response is critical for host survival, and fatal Lassa fever is often characterized by impaired or delayed cellular immunity[5].
Genetics
- Replication for Lassa virus is very rapid and demonstrates a temporal control.[6]
- The initial replication step is transcription of mRNA copies of the negative (minus-sense) genome. This process ensures an adequate supply of viral proteins for subsequent steps of replication, as the NP and L proteins are translated from the mRNA.
- Following the initial replication step, the positive (plus-sense) genome then synthesizes viral complementary RNA (vcRNA) copies of itself. The vcRNA copies are then used to synthesize more mRNA and to serve as templates for the production of more negative-sense progeny. The mRNA synthesized from vcRNA are then translated to produce GP and Z proteins.
- This temporal control allows the spike proteins to be produced last, and therefore, delay recognition by the host immune system.
Gross Pathology
Lassa virus commonly involves the liver and results in hepatocellular necrosis and apoptosis. Other organs may be involved, and Lassa fever infection may manifest with the following:[7][8][9]
- Splenic necrosis
- Adrenocortical necrosis
- Mononuclear interstitial myocarditis
- Pulmonary alveolar edema with capillary congestion and mild interstitial pneumonitis
- Lymph nodal sinus histiocytosis
- Gastrointestinal mucosal petechiae
- Renal tubular injury
- Interstitial nephritis
Microscopic Pathology
Typical features of Lassa fever-associated hepatitis include the following:
- Acidophilic necrosis
- Apoptotic changes
- Ballooning degeneration
- Pycnotic nuclei
- Microvascular changes
- Councilman bodies (intracellular inclusion bodies)
The images below display key features of microscopic pathology of Lassa virus.
-
This photomicrograph demonstrates hepatitis caused by the Lassa virus, using toluidine-blue azure II stain. Retrieved from the Public Health Image Library (PHIL) of the Centers for Disease Control and Prevention.Retrieved from the Public Health Image Library (PHIL), Centers for Disease Control and Prevention.[10]
-
This transmission electron micrograph (TEM) demonstrates the cytoarchitectural changes of a liver tissue specimen extracted from a patient with Lassa fever. The presence of a typical Councilman body, pycnotic nuclei in an area of acidophilic necrosis, and microvacuolar fatty changes are noted.Retrieved from the Public Health Image Library (PHIL), Centers for Disease Control and Prevention.[10]
-
Scanning electron micrograph (SEM) demonstrates the cytoarchitectural changes of a liver tissue specimen extracted from a patient with Lassa fever. A zone of acidophilic necrosis, and numbers of pycnotic nuclei are noted.Retrieved from the Public Health Image Library (PHIL), Centers for Disease Control and Prevention.[10]
-
Sudan III-stained photomicrograph demonstrates the cytoarchitectural changes of a liver tissue specimen extracted from a patient with Lassa fever. Microvacuolar fatty necrosis is noted.Retrieved from the Public Health Image Library (PHIL), Centers for Disease Control and Prevention.[10]
-
This photomicrograph demonstrates hepatitis caused by the Lassa virus, using toluidine-blue azure II stain, magnified 500X.Retrieved from the Public Health Image Library (PHIL), Centers for Disease Control and Prevention.[10]
References
- ↑ Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH; et al. (2000). "Genetic diversity among Lassa virus strains". J Virol. 74 (15): 6992–7004. PMC 112216. PMID 10888638.
- ↑ 2.0 2.1 Yun NE, Walker DH (2012). "Pathogenesis of Lassa fever". Viruses. 4 (10): 2031–48. doi:10.3390/v4102031. PMC 3497040. PMID 23202452.
- ↑ Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC (2006). "Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus". J Virol. 80 (18): 9192–9. doi:10.1128/JVI.00555-06. PMC 1563941. PMID 16940530.
- ↑ Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M; et al. (2010). "T cell-dependence of Lassa fever pathogenesis". PLoS Pathog. 6 (3): e1000836. doi:10.1371/journal.ppat.1000836. PMC 2847900. PMID 20360949.
- ↑ "The Centers for Disease Control and Prevention".
- ↑ Lashley FR (2006). "Emerging infectious diseases at the beginning of the 21st century". Online J Issues Nurs. 11 (1): 2. PMID 16629503.
- ↑ Frame JD, Baldwin JM, Gocke DJ, Troup JM (1970). "Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings". Am J Trop Med Hyg. 19 (4): 670–6. PMID 4246571.
- ↑ Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, Elliott LH; et al. (1982). "Pathologic and virologic study of fatal Lassa fever in man". Am J Pathol. 107 (3): 349–56. PMC 1916239. PMID 7081389.
- ↑ McCormick JB, Walker DH, King IJ, Webb PA, Elliott LH, Whitfield SG; et al. (1986). "Lassa virus hepatitis: a study of fatal Lassa fever in humans". Am J Trop Med Hyg. 35 (2): 401–7. PMID 3953952.
- ↑ 10.0 10.1 10.2 10.3 10.4 "Public Health Image Library (PHIL), Centers for Disease Control and Prevention".